1. Pharmaceuticals and Drug Development

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

WASHINGTON, Nov. 28, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness:
Partial Clinical Hold Re-Review Timeline
Under the collaborative…

Comments to: Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.